#USA #San Diego #Halozyme Therapeutics #ENHANZE Technology #Dr. Helen Torley

Halozyme's Upcoming Presentation at BofA 2025 Healthcare Conference

Halozyme Therapeutics, Inc., a pioneering biopharmaceutical firm listed on NASDAQ as HALO, is gearing up for an important event at the BofA Securities 2025 Healthcare Conference. Dr. Helen Torley, the company’s president and CEO, is scheduled to make a presentation on May 13, 2025, at 4:20 PM PT (7:20 PM ET). This presentation will delve into Halozyme's innovative advancements in drug delivery technology, particularly focusing on their proprietary ENHANZE® technology.

The BofA Securities Healthcare Conference is a pivotal venue for showcasing new developments in the health sector, and Halozyme's participation highlights its commitment to improving patient care through innovative solutions. Dr. Torley's presentation aims to enlighten investors about Halozyme's ongoing projects, collaborations, and the future trajectory of the company.

After the presentation, a live audio stream of the event will be accessible on the Investor Relations section of Halozyme's website. For those unable to attend, audio replays will be available for 90 days post-conference, ensuring stakeholders have ample opportunity to catch up on the crucial details shared.

About Halozyme

Headquartered in San Diego, California, Halozyme Therapeutics is at the forefront of transforming the biopharmaceutical landscape with its focus on enhancing the delivery and efficacy of various therapies. The company specializes in the ENHANZE® drug delivery platform, which uses the proprietary enzyme rHuPH20 to facilitate subcutaneous administration of injected medications. This approach is designed to optimize the patient experience by allowing for quicker delivery and reducing overall treatment burdens.

Halozyme’s technology has reached over a million patients globally across numerous commercialized products, indicating the efficacy and reliability of its innovations. The firm has successfully partnered with multiple leading pharmaceutical and biotech companies, including Roche, Takeda, and Pfizer, to enhance their therapies with ENHANZE® technology.

Additionally, Halozyme is involved in developing drug-device combination products utilizing advanced auto-injector technologies, further emphasizing their commitment to convenience and improved patient adherence.

With two proprietary products, Hylenex® and XYOSTED®, alongside synergistic partnerships with Teva Pharmaceuticals and others, Halozyme is actively shaping the future of therapeutic solutions. Their ongoing development programs continue to focus on enhancing patient comfort, reliability, and treatment experience, which is central to their mission.

As Halozyme prepares for this conference, industry watchers and investors alike are keen to understand how the company's innovative approaches and technology can redefine patient treatment protocols in a rapidly evolving healthcare landscape. For more detailed insights, interested parties can navigate to Halozyme’s website or follow their updates on LinkedIn and Twitter.

The confidence in Halozyme's commitment to advancing healthcare solutions is palpable as they continue to push boundaries and explore potential collaborations within the biopharmaceutical realm. Dr. Torley’s talk promises to shed light on how the company plans to leverage its technology to meet the increasing demands of patients and healthcare providers in the coming years.